These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17298581)

  • 1. Logistics of platelet concentrates.
    Vox Sang; 2007 Feb; 92(2):160-81. PubMed ID: 17298581
    [No Abstract]   [Full Text] [Related]  

  • 2. Bacterial contamination in platelet concentrates.
    Pietersz RN; Reesink HW; Panzer S; Oknaian S; Kuperman S; Gabriel C; Rapaille A; Lambermont M; Deneys V; Sondag D; Ramírez-Arcos S; Goldman M; Delage G; Bernier F; Germain M; Vuk T; Georgsen J; Morel P; Naegelen C; Bardiaux L; Cazenave JP; Dreier J; Vollmer T; Knabbe C; Seifried E; Hourfar K; Lin CK; Spreafico M; Raffaele L; Berzuini A; Prati D; Satake M; de Korte D; van der Meer PF; Kerkhoffs JL; Blanco L; Kjeldsen-Kragh J; Svard-Nilsson AM; McDonald CP; Symonds I; Moule R; Brailsford S; Yomtovian R; Jacobs MR
    Vox Sang; 2014 Apr; 106(3):256-83. PubMed ID: 24654780
    [No Abstract]   [Full Text] [Related]  

  • 3. Preparation, storage and quality control of platelet concentrates.
    Tynngård N
    Transfus Apher Sci; 2009 Oct; 41(2):97-104. PubMed ID: 19699153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated preparation of platelet concentrates from pooled buffy coats using the Gambro OrbiSac system.
    Gulliksson H; Sjödin A; Sandgren P; Vesterinen M; Larsson S; Diedrich B
    Transfus Apher Sci; 2003 Aug; 29(1):11-2. PubMed ID: 12877886
    [No Abstract]   [Full Text] [Related]  

  • 5. The hemostatic efficacy of platelet components prepared with pathogen inactivation.
    Corash L
    Transfusion; 2011 Jun; 51(6):1355-6; author reply 1356-7. PubMed ID: 21658040
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical aspects of treatment with platelet concentrates.
    Lanzer G
    Acta Anaesthesiol Scand Suppl; 1996; 109():141-3. PubMed ID: 8901986
    [No Abstract]   [Full Text] [Related]  

  • 7. Treating thrombocytopenia with pathogen-reduced platelets.
    Sandler SG
    Curr Hematol Rep; 2006 Mar; 5(1):53-4. PubMed ID: 16537046
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet concentrates, from whole blood or collected by apheresis?
    van der Meer PF
    Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of preparation and preservation modality on thrombocyte quality].
    Mohren M; Müller H; Körner K; Wiesneth M; Kubanek B; Heimpel H; Seifried E
    Beitr Infusionsther; 1993; 31():107-10. PubMed ID: 7693237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma.
    Vassallo RR; Adamson JW; Gottschall JL; Snyder EL; Lee W; Houghton J; Elfath MD
    Transfusion; 2010 Nov; 50(11):2376-85. PubMed ID: 20497516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet concentrates: functional considerations, storage, and quality control.
    Murphy S; Schiffer CA; Katz AJ
    J Clin Apher; 1983; 1(3):185-9. PubMed ID: 6546056
    [No Abstract]   [Full Text] [Related]  

  • 12. A critical comparison of platelet preparation methods.
    Vassallo RR; Murphy S
    Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
    Vasconcelos E; Figueiredo AC; Seghatchian J
    Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of leukocytes on the storage of platelet concentrates.
    Pietersz RN; de Korte D; Dekker WJ; Reesink HW
    Infusionstherapie; 1991 Jun; 18 Suppl 1():10-2. PubMed ID: 1917057
    [No Abstract]   [Full Text] [Related]  

  • 15. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets.
    Vamvakas EC
    Transfusion; 2011 May; 51(5):1058-71. PubMed ID: 21058955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The timing of leuko-depletion of apheresis platelets with a Sepacell PLS-5A filter does not affect glycoprotein IIb/IIIa-dependent platelet function in vitro.
    Müller TH; Schmidt S; Schunter F; Seghatchian MJ
    Transfus Sci; 1998 Dec; 19(4):389-92. PubMed ID: 10351165
    [No Abstract]   [Full Text] [Related]  

  • 17. Sterilization method of platelet storage containers affects in vitro parameters.
    van der Meer PF; Pietersz RN
    Vox Sang; 2007 Jan; 92(1):32-6. PubMed ID: 17181588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of washed and volume-reduced platelets with respect to platelet activation, aggregation, and plasma protein removal.
    Veeraputhiran M; Ware J; Dent J; Bornhorst J; Post G; Cottler-Fox M; Pesek G; Theus J; Nakagawa M
    Transfusion; 2011 May; 51(5):1030-6. PubMed ID: 20946201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative safety of buffy coat platelet pools.
    Devine D; Jenkins C; Howe D; Goldman M
    Transfusion; 2010 Jul; 50(7):1591-2; author reply 1592-3. PubMed ID: 20636534
    [No Abstract]   [Full Text] [Related]  

  • 20. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients.
    Vassallo RR
    Immunohematology; 2009; 25(3):119-24. PubMed ID: 20406018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.